GABA Transaminase Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “GABA Transaminase Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
GABA Transaminase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across GABA Transaminase Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the Report
Reasons to Buy
1. Report Introduction
2. GABA Transaminase Inhibitor - Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. GABA Transaminase Inhibitor Pipeline Products in Clinical Stages
6. GABA Transaminase Inhibitor Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active Products
8. Inactive Pipeline Products
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hnxzxg/gaba_transaminase?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005227/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/22/2019 07:36 AM/DISC: 02/22/2019 07:36 AM